ArticleMolecular biology of the cell2001
The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes.
Article in Molecular biology of the cell, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 154 citations in OpenAlex.
- Bora bridges Aurora-A activation and substrate recognition of PLK1.EMBO reports · 2026Article
- Article
- Article
- CDC6 as a Key Inhibitory Regulator of CDK1 Activation Dynamics and the Timing of Mitotic Entry and Progression.Biology · 2023Review
- Multiple Roles of PLK1 in Mitosis and Meiosis.Cells · 2023Review
- The G2-to-M transition from a phosphatase perspective: a new vision of the meiotic division.Cell division · 2020Review
- Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells.Scientific reports · 2019Article
- A unified view of spatio-temporal control of mitotic entry: Polo kinase as the key.Open biology · 2018Review
- USP39 regulates the growth of SMMC-7721 cells via FoxM1.Experimental and therapeutic medicine · 2017Article
- Structural basis for recognition of Emi2 by Polo-like kinase 1 and development of peptidomimetics blocking oocyte maturation and fertilization.Scientific reports · 2015Article
- Centrosomes as signalling centres.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2014Review
- Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1.PLoS neglected tropical diseases · 2014Article
- Phosphorylation-mediated stabilization of Bora in mitosis coordinates Plx1/Plk1 and Cdk1 oscillations.Cell cycle (Georgetown, Tex.) · 2014Article
- SRC-family tyrosine kinases in oogenesis, oocyte maturation and fertilization: an evolutionary perspective.Advances in experimental medicine and biology · 2014Review
- Budding yeast greatwall and endosulfines control activity and spatial regulation of PP2A(Cdc55) for timely mitotic progression.PLoS genetics · 2013Article
- Decoding ubiquitin for mitosis.Genes & cancer · 2012Article
- Pioneering the Xenopus oocyte and egg extract system.The Journal of biological chemistry · 2012Article
- The Polo-like kinase PLKA in Aspergillus nidulans is not essential but plays important roles during vegetative growth and development.Eukaryotic cell · 2012Article
- A dynamical model of oocyte maturation unveils precisely orchestrated meiotic decisions.PLoS computational biology · 2012Article
- Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.Nature communications · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
In the Xenopus oocyte system mitogen treatment triggers the G(2)/M transition by transiently inhibiting the cAMP-dependent protein kinase (PKA); subsequently, other signal transduction pathways are activated, including the mitogen-activated protein kinase (MAPK) and polo-like kinase pathways. To study the interactions between these pathways, we have utilized a cell-free oocyte extract that carries out the signaling events of oocyte maturation after addition of the heat-stable inhibitor of PKA, PKI. PKI stimulated the synthesis of Mos and activation of both the MAPK pathway and the Plx1/Cdc25C/cyclin B-Cdc2 pathway. Activation of the MAPK pathway alone by glutathione S-transferase (GST)-Mos did not lead to activation of Plx1 or cyclin B-Cdc2. Inhibition of the MAPK pathway in the extract by the MEK1 inhibitor U0126 delayed, but did not prevent, activation of the Plx1 pathway, and inhibition of Mos synthesis by cycloheximide had a similar effect, suggesting that MAPK activation is the only relevant function of Mos. Immunodepletion of Plx1 completely inhibited activation of Cdc25C and cyclin B-Cdc2 by PKI, indicating that Plx1 is necessary for Cdc25C activation. In extracts containing fully activated Plx1 and Cdc25C, inhibition of cyclin B-Cdc2 by p21(Cip1) had no significant effect on either the phosphorylation of Cdc25C or the activity of Plx1. These results demonstrate that maintenance of Plx1 and Cdc25C activity during mitosis does not require cyclin B-Cdc2 activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.